

Ovarian Cancer Market Key Topics Covered Such as Current Treatment Options, Unmet Needs, Opportunities & Forecast 2025

Orbisresearch.com added latest 280 pages report "OpportunityAnalyzer: Ovarian Cancer-Opportunity Analysis and Forecasts to 2025" in its store.

DALLAS, TEXAS, UNITED STATES, August 29, 2017

/EINPresswire.com/ -- [Ovarian cancer](#) is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.



Request a sample of this report @ <http://www.orbisresearch.com/contacts/request-sample/358335>

For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. GlobalData is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.

Key Questions Answered

- How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015-2025?
- What are the most promising late-stage pipeline drugs in ovarian cancer?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the unmet needs in ovarian cancer treatment management?
- What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?

Scope

- Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Buy a report @ <http://www.orbisresearch.com/contact/purchase/358335>

List of Figures

Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025	12
Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017	15
Figure 3: Selected Types of Ovarian Cancer and Other Closely Related Neoplasms	23
Figure 4: Risk Factors and Symptoms Suggestive of Ovarian Cancer	25
Figure 5: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 1998-2007	30
Figure 6: 7MM, Diagnosed Incident Cases of OC, Ages ≥ 18 Years, N, 2015-2025	36
Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015	38
Figure 8: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages ≥ 18 Years, Cases per 100,000, 2015	39
Figure 9: 7MM, Diagnosed Incident Cases of PPC, Ages ≥ 18 Years, N, 2015-2025	40
Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥ 18 Years, N, 2015-2025	42
Figure 11: Top-Level Treatment Flow Chart for Ovarian Cancer Patients	48
Figure 12: Clinical Development Program for Avastin in Ovarian Cancer	53
Figure 13: Clinical Development Program for Lynparza in Ovarian Cancer	63
Figure 14: Clinical Development Program for Rubraca in Ovarian Cancer	72
Figure 15: Clinical Development Program for Zejula in Ovarian Cancer	78
Figure 16: Clinical Development Program for Yondelis in Ovarian Cancer	83
Figure 17: Clinical Development Program for Bavencio in Ovarian Cancer	131
Figure 18: Clinical Development Program for Opdivo in Ovarian Cancer	136
Figure 19: Clinical Development Program for Tecentriq in Ovarian Cancer	142
Figure 20: Clinical Development Program for Vigil in Ovarian Cancer	148
Figure 21: Clinical Development Program for Fosbretabulin in Ovarian Cancer	153
Figure 22: Clinical Development Program for Veliparib in Ovarian Cancer	160
Figure 23: Clinical Development Program for Mirvetuximab Soravtansine in Ovarian Cancer	165
Figure 24: Clinical Development Program for Opaxio in Ovarian Cancer	170
Figure 25: Clinical Development Program for Lurbinectedin in Ovarian Cancer	175
Figure 26: Clinical Development Program for Apealea in Ovarian Cancer	180
Figure 27: Clinical Development Program for Cediranib in Ovarian Cancer	192
Figure 28: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017	211
Figure 29: Sales for Ovarian Cancer Products by Region, 2015-2025	214

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Hector Costello
Orbis Research

+1 (214) 884-6817

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/400782796>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.